Kexing Biopharm
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese vaccine and infectious disease biopharma company, developer of the widely used CoronaVac COVID-19 vaccine.
Infectious Disease
Technology Platform
Platforms for inactivated virus vaccines and recombinant protein-based vaccines, with ongoing development in mRNA technology.
Opportunities
Expanding its international vaccine portfolio and leveraging its massive manufacturing infrastructure for future pandemic preparedness contracts.
Risk Factors
Heavy reliance on CoronaVac revenues and potential decline in demand as the pandemic phase ends, coupled with technological disruption from mRNA platforms.
Competitive Landscape
Competes with state-owned Sinopharm in traditional vaccines and faces future competition from mRNA innovators like BioNTech and Moderna in new indications.